Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker, Konstantinos E. Tsaparikos, Donald E. Sloan, James D. Moyer, Elsa G. Barbacci, Leslie R. Pustilnik, Teresa A. Smolarek, John A. Davis, Madhur P. Vaidya, Lee D. Arnold, John L. Doty, Kenneth K. Iwata and Michael J. Morin
Journal of Pharmacology and Experimental Therapeutics November 1999, 291 (2) 739-748;
Vincent A. Pollack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas M. Savage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah A. Baker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos E. Tsaparikos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald E. Sloan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Moyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elsa G. Barbacci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie R. Pustilnik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa A. Smolarek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhur P. Vaidya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee D. Arnold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John L. Doty
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth K. Iwata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Morin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr) is an important early event in signal transduction, leading to cell replication for major human carcinomas. CP-358,774 is a potent and selective inhibitor of the EGFr tyrosine kinase and produces selective inhibition of EGF-mediated tumor cell mitogenesis. To assess the pharmacodynamic aspects of EGFr inhibition, we devised an ex vivo enzyme-linked immunosorbent assay for quantification of EGFr-specific tyrosine phosphorylation in human tumor tissue specimens obtained from xenografts growing s.c. in athymic mice. When coupled with pharmacokinetic analyses, this measurement can be used to describe the extent and duration of kinase inhibition in vivo. CP-358,774 is an effective, orally active inhibitor of EGFr-specific tyrosine phosphorylation (ED50 = 10 mg/kg, single dose). It has a significant duration of action, producing, on average, a 70% reduction in EGFr-associated phosphotyrosine over a 24-h period after a single 100 mg/kg dose. Inhibition of EGFr phosphotyrosine in an ex vivo assay format effectively estimates the potency and degree of inhibition of EGFr-dependent human LICR-LON-HN5 head and neck carcinoma tumor growth. Substantial growth inhibition of human tumor xenografts was achieved with p.o. doses of the compound (ED50 = 10 mg/kg q.d. for 20 days). Combination chemotherapy with cisplatin produced a significant response above that of cisplatin alone with no detectable effects on body weight or lethal toxicity. Taken together, these observations suggest that CP-358,774 may be useful for the treatment of EGFr-driven human carcinomas.

Footnotes

  • Send reprint requests to: Dr. Vincent A. Pollack, Department of Genomics, Targets and Cancer Research, Pfizer Central Research, Eastern Point Road, Groton, CT 06340. E-mail:vincent_a_pollack{at}groton.pfizer.com

  • ↵1 Portions of this work were presented at the annual meeting of the American Association for Cancer Research, April 1997.

  • ↵2 Present address: Department of Chemistry, BASF Bioresearch Corp., 100 Research Dr., Worcester, MA 01605-4314.

  • ↵3 Address: OSI Pharmaceuticals, Inc., 106 Charles Lindbergh Blvd., Uniondale, NY 11553.

  • Abbreviations:
    EGF
    epidermal growth factor
    EGFr
    epidermal growth factor receptor
    ELISA
    enzyme-linked immunosorbent assay
    HBSS
    Hanks’ balanced salt solution
    HN5
    LICR-LON-HN5 head and neck carcinoma
    • Received May 18, 1999.
    • Accepted August 5, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 291 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 291, Issue 2
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker, Konstantinos E. Tsaparikos, Donald E. Sloan, James D. Moyer, Elsa G. Barbacci, Leslie R. Pustilnik, Teresa A. Smolarek, John A. Davis, Madhur P. Vaidya, Lee D. Arnold, John L. Doty, Kenneth K. Iwata and Michael J. Morin
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 739-748;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker, Konstantinos E. Tsaparikos, Donald E. Sloan, James D. Moyer, Elsa G. Barbacci, Leslie R. Pustilnik, Teresa A. Smolarek, John A. Davis, Madhur P. Vaidya, Lee D. Arnold, John L. Doty, Kenneth K. Iwata and Michael J. Morin
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 739-748;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interactive Role for Neurosteroids in Ethanol Enhancement of γ-Aminobutyric Acid-Gated Currents from Dissociated Substantia Nigra Reticulata Neurons
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics